DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection.


File Description SizeFormat
JHBPS15_627.pdf371.1 kBAdobe PDFView/Open

Title: Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection.
Authors: Eguchi, Susumu / Matsumoto, Shigehiro / Hamasaki, Koji / Takatsuki, Mitsuhisa / Hidaka, Masaaki / Tajima, Yoshitsugu / Sakamoto, Ichiro / Kanematsu, Takashi
Issue Date: Nov-2008
Publisher: Springer Japan
Citation: Journal of hepato-biliary-pancreatic surgery, 15(6), pp.627-633; 2008
Abstract: BACKGROUND/PURPOSE: While lipiodolized transarterial chemoembolization (lip-TACE) is effective for treating unresectable hepatocellular carcinoma (HCC), its effect for treating recurrent HCC after curative liver resection needs to be clarified. METHODS: Of 163 patients who had undergone curative liver resection between 1992 and December 2003, 65 patients (39.8%) had recurrent HCC in the liver without extrahepatic recurrence and were indicated for lip-TACE. The overall survival rate after lip-TACE was calculated, and its correlation with factors such as the histology of the primary HCC and background noncancerous tissue were analyzed. RESULTS: The overall survival rates after lip-TACE after the detection of the first recurrent HCC were 82.6%, 44.5%, and 24.8% at 1, 3, and 5 years, respectively. The factors affecting patient survival after lip-TACE were microscopic portal venous involvement of HCC at liver resection, grade of inflammation in the noncancerous liver parenchyma, and recurrence within 1 year after the initial liver resection. Multivariate analysis showed that the period between the resection and first recurrence had the highest hazard ratio. CONCLUSIONS: Lip-TACE is a reasonable procedure for treating recurrent HCC in selected patients who are not eligible for hepatic re-resection. When HCC recurred within 1 year from the primary liver resection, the effect of lip-TACE on patient survival was limited.
Keywords: Hepatocellular carcinoma / Lipiodolized chemoembolization / Recurrence / Resection
URI: http://hdl.handle.net/10069/22709
ISSN: 09441166
DOI: 10.1007/s00534-007-1341-3
PubMed ID: 18987934
Rights: © Springer Japan 2008. / The original publication is available at www.springerlink.com
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/22709

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace